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Abstract: BACKGROUND To describe 10-year trends in visual outcomes, anatomical outcomes and
treatment burden of patients receiving antivascular endothelial growth factor (anti-VEGF) therapy
for neovascular age-related macular degeneration (nAMD). METHODS Retrospective cohort study of
treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The pri-
mary outcome was time to best-corrected visual acuity (BCVA) falling ฀35 ETDRS letters after initiating
anti-VEGF therapy. Secondary outcomes included time to BCVA reaching ฀70 letters, proportion of eyes
with BCVA ฀70 and ฀35 letters in 10 years, mean trend of BCVA and central retinal thickness over 10
years, and mean number of injections. RESULTS For our cohort of 103 patients, Kaplan-Meier analyses
demonstrated median time to BCVA reaching ฀35 and ฀70 letters were 37.8 (95% CI 22.2 to 65.1) and 8.3
(95% CI 4.8 to 20.9) months after commencing anti-VEGF therapy, respectively. At the final follow-up,
BCVA was ฀35 letters and ฀70 letters in 41.1% and 21%, respectively, in first-affected eyes, while this was
the case for 5.4% and 48.2%, respectively, in a patient’s better-seeing eye. Mean injection number was
37.0±24.2 per eye and 53.6±30.1 at patient level (63.1% of patients required injections in both eyes).
CONCLUSIONS The chronicity of nAMD disease and its management highlights the importance of long-
term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ฀70
ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two
patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment
of nAMD is associated with better visual outcomes.
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Background:​ To describe 10-year trends in ​visual outcomes, anatomical outcomes, and 
treatment burden ​of patients receiving anti-vascular endothelial growth factor (VEGF) therapy 
for neovascular age-related macular degeneration (nAMD). 
Methods:​ Retrospective cohort study of treatment-naïve, first-affected eyes with nAMD started 
on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual 
acuity (BCVA) falling ≤ 35 early treatment diabetic retinopathy study (ETDRS) letters after 
initiating anti-VEGF therapy. Secondary outcomes included time to BCVA reaching ≥ 70 letters; 
proportion of eyes with BCVA ≥ 70 and ≤ 35 letters at 10 years; mean trend of BCVA and 
central retinal thickness (CRT) over 10 years; and mean number of injections. 
Results:​ For our cohort of 103 patients,​ Kaplan-Meier analyses demonstrated median time to 
BCVA reaching ≤35 and ≥70 letters were 37.8 (95% CI 22.2-65.1) and 8.3 (95% CI 4.8-20.9) 
months after commencing anti-VEGF therapy, respectively. At the final follow-up, BCVA was 
≤35 letters and ≥70 letters in 41.1% and 21%, respectively, in first-affected eyes, whilst this was 
the case for 5.4% and 48.2%, respectively, in a patient’s better-seeing eye. Mean injection 
number was 37.0 ± 24.2 per eye and 53.6 ± 30.1 at patient-level (63.1% of patients required 
injections in both eyes).  
Conclusions:​ ​The chronicity of nAMD disease and its management highlights the importance of 
long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision 
(BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF 
treatment; yet one in two patients will have good vision in their better-seeing eye. Moreover, our 




AMD - age related macular degeneration 
GA - geographic atrophy  
CNV - choroidal neovascularization 
UK - United Kingdom 
nAMD - neovascular AMD  
VEGF - vascular endothelial growth factor 
RCT - randomized controlled trial 
MEH -  Moorfields Eye Hospital  
BCVA - best-corrected visual acuity 
ETDRS - Early Treatment Diabetic Retinopathy Study 
CRT - central retinal thickness 
OCT - optical coherence tomography 
PRN - pro re nata 
LTFU - lost to follow-up 
DNA - did not attend 
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Age-related macular degeneration (AMD) is a progressive disease which frequently 
necessitates long-term treatment. Photoreceptor dysfunction is likely to occur, with the 
development of geographic atrophy (GA) and choroidal neovascularization (CNV). ​[1]​ Left 
untreated, CNV leads to legal blindness in 76% of individuals at 3 years. ​[1,2]​ In the United 
Kingdom (UK), it is estimated that 1 in every 2000 individuals aged 60 or over are diagnosed 
with late AMD, defined as GA or CNV, rising to 1 in every 5 individuals aged 90 or more.​[3]​ Over 
40,000 individuals are diagnosed with neovascular AMD (nAMD) in the UK every year. ​[4] 
Intravitreal injections of anti-vascular endothelial growth factor (VEGF) have been proven to be 
the most effective treatment for nAMD,​[5–7]​ although there is a lack of supported data from 
randomized controlled trials (RCTs) on long-term outcomes.​[8–10]​ The unquestionable level of 
benefit achieved in RCTs is nonetheless seldom achieved in a real-life setting, as per selection 
criteria, monthly assessments, and strict treatment protocols. Furthermore, long-term RCTs 
would be cost-prohibitive. In clinical practice, frequent examinations can pose an added burden 
to the overstretched healthcare system. The question of whether a frequent dosing regimen in 
the first 1-2 years of treatment could grant better long-term visual outcomes, or if it delays a 
drop in vision occurring when adopting a less frequent dosing regimen, remains unanswered. 
Additionally, morphological changes, such as GA, may be either the result of cumulative 
damage over years, or the presumed effect of persistent VEGF blockage. As the long-term 
natural history of nAMD is discouraging, one of the biggest challenges is preserving patients’ 
expectations and level of independence in activities of daily living. 
 
 
This study aimed to interrogate the 10-year visual function, anatomical outcome, and treatment 
burden of anti-VEGF treatment in the first-affected eye of nAMD patients. These findings inform 
long-term prognosis and treatment expectations, with potential impact on promoting patient 
engagement. Moreover, a deidentified version of our dataset and its analysis in step-by-step 
code will be made open-source digital to permit replication, follow-up analyses, and promote 








This was a retrospective cohort study of patients that had commenced intravitreal therapy for 
nAMD at Moorfields Eye Hospital (MEH) NHS Foundation Trust before January 1, 2009. 
Baseline was defined as the date of the first injection of the first-affected eye. Final visit was 
defined as the appointment nearest to and within 6 months of 120 months from baseline. Data 
extracted from electronic medical records included demography, appointment date, anti-VEGF 
agent administered, and fellow eye involvement for each visit. All data points were manually 
cross-referenced by three researchers. For each appointment, best-corrected visual acuity 
(BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters and central retinal 
thickness (CRT) were extracted. This study was conducted in accordance with the Declaration 
of Helsinki and the UK’s Data Protection Act. Permission for data collection and analysis was 
registered as a clinical audit (reference CA17/MR/28). 
 
Cohort selection 
Eligibility criteria were: (i) age ≥ 50; (ii) treatment with ranibizumab ​0​.5 mg/0.05 mL (Lucentis; 
Genentech, South San Francisco, CA) for nAMD before January 1, 2009; (iii) treatment-naïve 
eyes; (iv) first-affected eye. Exclusion criteria were: (i) previous/concomitant treatment with 
photodynamic therapy or macular laser; (ii) previous treatment with intravitreal bevacizumab, 
pegaptanib or ranibizumab; (iii) missing baseline BCVA; (iv) macular scar secondary to nAMD in 





All patients were started on a ​pro re nata ​(PRN) ranibizumab regimen until 2015, when a 
treat-and-extend protocol was adopted. All eyes were treated according ​to ​MEH AMD 
intravitreal treatment guidelines ​(​Supplementary Figure 1​).​[13]​ Briefly, all patients starting on 
ranibizumab undergo 3 monthly injections, followed by a PRN treatment if dry. They are 
otherwise offered a treat-and-extend protocol i.e. monthly injections until dry after which 
injection visits increase by 2-week increments up to 12 weekly injections. If a patient undergoes 
12-weekly injections for 3 consecutive visits alongside features of stability, they are monitored at 
6-weekly intervals for 6 months without injections and then at 3-monthly intervals without 
injections. Here, disease stability (or disease inactivity) is defined as absence of the following 
features when compared with the previous visit: new or enlargement of fluid on OCT; new or 
persistent haemorrhage or exudates; decreased VA attributable to CNV; fluorescein leakage or 
increase in lesion size on FFA. Disease stability at the last follow-up appointment was assessed 
by considering whether patients had received anti-VEGF treatment in the 6 months leading up 
to and including the last appointment. Those who responded suboptimally to ranibizumab were 
switched to aflibercept 2 mg/0.05 mL (Eylea; Regeneron, Tarrytown, NY). 
 
 
Loss to follow-up 
Patients who did not reach the 10-year timepoint were considered lost to follow-up (LTFU). 
Underlying reasons for LTFU were categorised as: deceased; non-attendance of appointments 
despite physician’s recommendation (DNA; did not attend); clinician decision to discharge; or 





SD-OCT scans and colour fundus photographs (CFP) at baseline and last visit were reviewed 
by two reading centre graders to assess morphological features, including: CNV type, 
intraretinal fluid (IRF), subretinal fluid (SRF), foveal/extrafoveal GA or fibrotic scar, subretinal 
hyperreflective material, intraretinal/subretinal haemorrhages. GA was defined on OCT as 
presence of ≥ 1 patch, within the macular vascular arcades, of partial/complete retinal pigment 
epithelium or outer retinal atrophy ≥ 250 μm, increase in choroidal reflectivity below Bruch’s 
membrane, external limiting membrane absence/descent, and sharply demarcated borders, 
and/or visibility of underlying choroidal vessels on CFP.​[14,15]​ CRT values were extracted using 
Topcon OCT Data Collector Software. This was defined as ​thickness from inner limiting 
membrane to outer photoreceptor segments/retinal pigment epithelium junction boundary within 
the ​ central ETDRS grid region when centred on the fovea ​. Manual measurements of CRT were 
performed on OCT scans at fixed time points to check for accuracy.  
 
Outcome measures 
The primary outcome was time to BCVA falling to or below 35 ETDRS letters after starting 
anti-VEGF therapy. Secondary outcomes were: time to BCVA reaching 70 letters or above; 
proportion of first-affected eyes with BCVA ≥ 70 and ≤ 35 letters at 10 years; proportion of 
patients with better-seeing eye BCVA ≥ 70 and ≤ 35 letters at 10 years; mean BCVA and CRT 
over the observation period; mean change in BCVA and CRT from baseline over the 





Statistical analyses were performed in R (R Foundation for Statistical Computing, Vienna, 
Austria; ​https://www.R-project.org/​).​[17]​ Cox proportional hazards regression models were 
performed to evaluate the effects of demography (gender, ethnicity), baseline features (age and 
BCVA) as time-independent continuous variables, and intravitreal injections (included as 
time-dependent covariates) on each outcome. 
Time to each of the visual outcomes were visualised with Kaplan-Meier time-event plots. 
Patients lost to follow-up during the observation period were censored. Survival plots were 
stratified by covariates identified as statistically significant in the Cox models. For visualisation 
purposes, baseline BCVA was sub-stratified into ≥ 70, 50-69, 36-49, and ≤ 35; and baseline age 
sub-stratified into ≥80, 70-79, and 60-69. 
Data distribution was tested by the Shapiro-Wilk test. Means of non-parametric groups were 
compared using Wilcoxon Signed-rank, Wilcoxon Rank-sum, and Kruskal-Wallis tests as 
appropriate. For more than two groups, multiple pairwise-analyses were carried out with the 
Wilcoxon Rank-sum test. P-value <0.05 was considered statistically significant. Mean values are 
expressed with ± standard deviation unless otherwise specified. 
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Data were extracted for 8,467 eyes of 6,778 patients receiving a total of 122,010 anti-VEGF 
injections for nAMD at MEH between June 2007 and July 2018. Before 1 January 2009, 128 
treatment-naïve eyes of 122 patients received intravitreal ranibizumab for nAMD. The cohort 
taken forward for analysis comprised 103 eyes from 103 patients, of which 56 patients (54.4%) 
were followed-up for the whole ten-year duration ( ​Figure 1 ​). Mean baseline BCVA was 54.6 ± 
14.9 ETDRS letters, with 26 (25.2%) patients having BCVA ≥ 70 letters, and 19 (18.4%) patients 
having BCVA ≤ 35 letters ( ​Table 1 ​). 
 
Visual outcomes 
Time to event analyses revealed median event time for reaching BCVA ≤ 35 letters to be 37.8 
(95% CI 22.2-65.1) months ( ​Figure 2 ​), and 8.3 (95% CI 4.8-20.9) months for reaching BCVA ≥ 
70 letters (​Figure 3 ​). Cox modelling was used to interrogate gender, baseline age, baseline 
BCVA and foveal thickness, and number of injections as covariates for reaching BCVA ≤ 35 and 
≥ 70 letters. Reaching BCVA ≤ 35 letters was negatively associated with baseline BCVA (HR 
0.91; 95% CI 0.89-0.94) and positively associated with age (HR 1.08; 95% CI 1.04-1.12). 
Conversely, BCVA ≥ 70 letters was only positively associated with baseline BCVA (HR 1.13; 
95% CI 1.10-1.17). To illustrate the association of baseline BCVA on these outcomes, we 
stratified our cohort into four groups: baseline BCVA ≤ 35, 36-49, 50-69, and ≥ 70 letters. 
The observed trend in mean BCVA change from baseline showed increases at month 6 (+1.9 ± 
14.5 letters) and month 12 (+2.6 ± 16.5). All subsequent timepoints exhibited negative and 
 
 
progressively decreasing mean VA-change peaking at -13.7 ± 6.5 at 120 months ( ​Figure 4 ​ and 
Supplementary Table 1 ​).  
At the 10 year follow-up timepoint, mean BCVA was 42.9 ± 27.0 letters and the proportion of 
eyes with BCVA ≥ 70 and ≤ 35 letters were 21.4% and 41.1%, respectively ( ​Table 2 ​). However, 
when visual outcomes were considered at the patient-level (i.e. the better-seeing eye), 48.2% 
had BCVA ≥ 70 letters in at least one eye and only 5.4% of the patients had BCVA ≤ 35 letters 
in both eyes (​Supplementary Figure 2) ​.​ Interestingly, each of the better-seeing eyes with 




Mean total number of injections per eye at 10 years was 37.0 ± 24.2. Of those who completed 
the follow-up, 29 (51.8%) were receiving injections at the 10 year timepoint ( ​Table 2 ​). Mean 
number of injections was 5.3 ± 3.1, 3.3 ± 2.8 and 3.0 ± 2.9 during years 1, 2 and 3, respectively, 
to decrease to 1.1 ± 2.2 during year 10 ( ​Supplementary Table 3 ​). Over the observation period, 
65 patients (63.1%) required injections in both eyes. Mean time to fellow eye involvement was 
30.6 ± 30.5 months. Mean total number of injections per patient, inclusive both first and second 
eye, was 53.6 ± 30.1 up to 10 years. All eyes started treatment with ranibizumab, and 60 
(58.3%) were switched to aflibercept after an average of 65.6 ± 9.5 months following baseline 




Anatomic observations and OCT features  
Average CRT was 298.9 ± 92.6 μm at baseline and 237.5 ± 87.3 μm at 10 years. An initial 
decline of 55.8 μm in CRT was evidenced at 6 months from baseline and maintained until year 
7, increasing to baseline values at year 9 ( ​Supplementary Table 2​). 
At 10 years, 21 eyes (37.5%) had IRF only, 5 (8.9%) had SRF only, and 3 (5.4%) had both IRF 
and SRF, while 43 (76.8%) and 32 (57.1%) presented GA and fibrotic scar, respectively. Median 
event time to GA was 44.8 months ( ​Supplementary Figure 3)​. We further stratified patients 
according to foveal involving lesions, where 5 patients (8.9%) had foveal-involving GA, and 21 
(37.5%) had subfoveal fibrosis. OCT images were examined to investigate morphological 
outcomes in eyes with poor BCVA (≤ 35 letters) at 10 years; foveal-involving fibrosis was the 
most common cause, accounting for 70% of this subcohort, followed by foveal GA (17%) and 
subfoveal IRF/SRF (13%). Cox modelling suggested that gender, baseline age, baseline BCVA 
and foveal thickness, and number of injections were not statistically significant covariates for 
development of GA ( ​Supplementary Figure 3 ​). Here we also queried baseline OCT features. 
Presence of IRF was positively associated with GA development (HR 2.21; 95% CI 1.02-4.79) 
while SRF was negatively associated with it (HR 0.52; 95% CI 0.28-0.97). 
 
Loss to follow-up  
Forty-seven patients (45.6%) were LTFU before 10 years. Mean time for LTFU was 61.0 ± 32.3 
months (​Table 2 ​). The main cause was death, represented by 42.6% of this cohort, followed by 
DNA patients (34.0%). Fifty-six percent of the DNA patients received their last injection 6 
months or more prior to their last visit. Thirteen percent of LTFU patients were discharged as 
 
 
per clinician’s opinion, with a median time to event at 49.5 months. ​A comparison of baseline 
demographics and clinical features was made between subgroups of patients who did and did 
not complete the 10-year follow-up; patients who completed it were younger at the time of first 
injection compared to LTFU patients (74.6 ​± 5.7 ​ vs 81.8 ​± 5.8 ​ years, respectively; p-value 
<0.001), but no difference was found between the two cohorts in terms of baseline BCVA, 





This study offers one of the longest reports on anti-VEGF treatment for nAMD and one of the 
first UK-based studies on patients followed-up for 10 years.​[18]​ ​By analysing results for the 
first-affected eye and accounting second eye involvement ​, we offer a realistic insight of disease 
burden and visual prognosis. Encouragingly, among those who completed the follow-up, 
approximately one out of two patients was able to maintain a BCVA ≥ 70 letters in the 
better-seeing eye while only 5.4% of the patients were accounted as legally blind at 10 years. 
By illustrating visual outcomes through survival curves, we hope to provide clinicians information 
which could be easily conveyed to patients. ​ ​As expected, poor visual outcomes could be 
deferred by early treatment. 
TIme event analyses revealed that median time to BCVA ≤ 35 letters was approximately 
3 years, which was negatively associated with baseline BCVA and positively associated with 
age. Patients with baseline BCVA between 36 and 49 letters were 50% likely for BCVA to fall ≤ 
35 letters 1.5 years after starting treatment, while patients with baseline BCVA ​>​70 letters had 
the same likelihood of reaching ≤ 35 letters after almost 8 years. This suggests that treating 
patients at an earlier stage (with higher VA and younger age) could delay poor visual outcomes. 
Noticeably, while patients with baseline BCVA ≤ 35 letters were not observed to achieve good 
BCVA (≥ 70 letters), patients with baseline BCVA ≥ 70 letters could achieve poor BCVA (≤ 35 
letters). This might be a reason for maintaining a close follow-up with those with good vision 
instead of discharging them, supported by the evidence that treatment is frequently resumed in 




More than half of our cohort were followed-up after 10 years (54%) and approximately 
half of these were still receiving treatment. This rate of attendance is greater than those 
reported in other RCTs and real-life studies,[9,10,20–24] ​with death being the main cause of 
LTFU. First-affected eyes received a mean 37.04 ± 24.19 injections over the whole observation 
period, comparably to a recent report on 10-year outcomes of a Swiss cohort. ​[24]​ Sixty-three 
percent of our patients required bilateral injections by a median time of approximately 2.5 years, 
with a ​total number of injections per patient, considering both the first and the second eye, 
corresponding to a mean of 53.6 ± 30.1 injections over 10 years. ​As no previous studies have 
investigated bilateral involvement at 10 years, comparison of long-term outcomes is limited to 
studies with shorter follow-up, such as the SEVEN-UP study (bilateral involvement of 51% at 7 
years). Of note, it has been put forth that the participants of the SEVEN-UP study were 
potentially under-treated at the beginning thereby limiting the visual potential. 
When considering short-term outcomes, the 2-year mean BCVA change observed 
amongst our cohort (-0.3 letters) was inferior to major RCTs, including PrONTO (+11.1 letters), 
MARINA (+7.2 letters), and ANCHOR (+11.3 letters).​[16,25,26]​ These differences could be 
partially attributable to baseline differences, as patients with poor baseline BCVA are usually 
excluded by RCTs. Patients recruited for the ANCHOR and MARINA trials were not all 
treatment-naïve and received monthly injections for 2 years. In contrast, ​our patients received 
about five injections in the first year, and three injections in both the second and third year. This 
was lower compared to the aforementioned RCTs and to other real-life studies. ​[9,10,27,28]​ A 
model-based analysis on VA-guided treatment regimen showed that 8.1 injections over the first 
and 6 over the second year were necessary to maintain the vision gained during the loading 
phase, ensuring the same efficacy as pivotal trials with less injections.​[29]​ This could partially 
 
 
explain why, in our study, the letters gained in the first year were not maintained at two years; 
insufficient treatment of our cohort cannot be ruled out, leaving space for additional 
improvement. 
At 10 years, the proportion of first-affected eyes with BCVA ≥ 70 and ≤ 35 letters were 
21.4% and 41.1%, respectively. Considering other real-life studies, similar proportions of eyes 
with BCVA ≥ 70 letters were reported,​[23,30]​ while Gillies​ et al.​ reported discordant outcomes 
between their two groups.​[24]​ ​To query visual function, we considered ​these visual outcomes at 
the patient-level. At 10 years, almost half of the patients retained a single eye with BCVA ≥ 70 
letters - the minimum threshold for a driver’s licence in most European countries and for reading 
small prints. Only 5.4% of the patients had BCVA ≤ 35 letters in the better-seeing eye i.e. ≤ 35 
letters in both eyes and potentially certifiable as visually impaired in the UK. ​[32] 
Anatomical analysis in a subcohort of patients with final BCVA ≤ 35 letters suggested 
that poor vision was more likely due to foveal fibrosis rather than foveal GA, as the proportion of 
eyes with subfoveal scarring and foveal GA was 70% and 17%, respectively. Overall, at 10 
years, 51.8% of our patients had evidence of exudation, while the incidence of subfoveal fibrosis 
was analogous to the one detected in the SEVEN-UP study (37.5% vs. 38.6%, respectively). 
Furthermore, we detected GA in 76.8% of our patients, with median time to GA development 
(approximately 4 years) being temporally concomitant with a drop of mean BCVA under its 
baseline values.​[30,33]​ Interrogating predictive factors of GA development is beyond the 
purpose of this study, but our survival analyses did not reveal an association between the 
number of injections and development of GA, in agreement with the HARBOR and SEVEN-UP 
studies.​[33,34]​ GA might be part of a degeneration caused by the disease itself and develop 
 
 
insofar as intravitreal therapy is administered at the onset of a more flogogenous process like 
exudation. 
This report has some limitations, including the retrospective observational study design, 
lack of a uniform treatment protocol, heterogeneous treatment intervals and patients’ 
management ​at the discretion of different physicians ​. Nonetheless, such heterogeneity is 
implicit in real-life studies and reflects routine medical practice, and retrospective studies 
represent the only affordable option to investigate long-term outcomes. ​We should remark that 
we excluded patients whose fellow eye was affected by advanced AMD, as second-treated eyes 
maintain better vision at all time points.​[36]​ ​Given these strict inclusion/exclusion criteria and 
data collection at each visit, this study offers a plausible real-life overview of outcomes 10 years 
after the commencement of nAMD treatment. 
Here we present a deidentified, real-world dataset of treatment-naïve, first-affected eyes 
from nAMD patients treated with anti-VEGF over a 10-year observation period. Our analyses 
reveal insights into the long-term visual and anatomical prognosis of anti-VEGF therapy and 
suggest that initiating treatment at early stages of disease may improve likelihood of achieving 
good vision and delay deterioration towards poor vision. Moreover, these data may inform policy 
and planning of healthcare service delivery, as well as enable patients to gain further 
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Figure 1.​ Figure shows the number of patients who received anti-VEGF injections for 
neovascular age-related macular degeneration (nAMD) between June 2007 and July 2018. 
Before 1 January 2009, 128 treatment-naïve eyes of 122 patients received intravitreal injections 
for nAMD; 6 patients were treated in both eyes in the selected time period, hence only the 
first-affected eye was taken forward for statistical analysis; 18 patients were excluded as they 
presented a pre-existing contralateral disciform scar at baseline; 1 patient was excluded due to 
missing baseline BCVA. The evaluable sample consisted of 103 eyes from 103 patients; of 
these, 56 patients (54.4%) were followed-up for the whole ten-year duration. 
  
Figure 2.​ Kaplan-Meier plot for time to reach visual acuity (VA) ≤ 35 letters (20/200) for all 
patients (top panel), as well as, sub-stratified by age groups (middle panel) and visual acuity at 
baseline (bottom panel) - 20 [20/400] ETDRS letters [Snellen equivalent]), 30 [20/250], 40 
[20/160], 50 [20/100], 60 [20/63], 70 [20/40], 80 [20/25]). ​As reaching VA ≤ 35 is the event, the 
y-axis represents the inverse of the event (VA ​>​ 36) i.e. as more patients reach VA ≤ 35 the 
probability of VA remaining ​>​ 36 and never reaching 35 falls. Cox-modelling was carried out with 
gender, baseline age, baseline best-corrected VA, baseline central retinal thickness (CRT), and 
injection number included as covariates. Hazard ratios (HR), 95% confidence intervals (CI), and 
p-values are displayed for the individual covariate. 
  
Figure 3. ​Kaplan-Meier plot for time to reach visual acuity (VA) ≥ 70 letters (20/40) for all 
patients (top panel), as well as, sub-stratified by visual acuity at baseline (bottom panel) - 20 
 
 
[20/400] ETDRS letters [Snellen equivalent]), 30 [20/250], 40 [20/160], 50 [20/100], 60 [20/63], 
70 [20/40], 80 [20/25]). ​As reaching VA ​>​ 70 is the event, the y-axis represents the inverse of 
the event (VA ​<​ 69) i.e. as more patients reach VA ​>​ 70 the probability of VA remaining ​<​ 69 
and never reaching 70 even once falls. Cox-modelling was carried out with gender, baseline 
age, baseline best-corrected VA, baseline central retinal thickness (CRT), and injection number 
included as covariates. Hazard ratios (HR), 95% confidence intervals (CI), and p-values are 
displayed for the individual covariate. 
 
Figure 4.​ Mean trends in visual acuity (VA) of first-affected eyes with nAMD. Mean VA (a) and 
mean change in VA following baseline (b) in early treatment diabetic retinopathy study (ETDRS) 
letters over the 120 month observation period. Baseline was considered timepoint at which the 









Patients, n (%)  103 56 (54.36%) 47 (45.63%)  
Gender (%) Female 75 (72.8) 41 (73.2) 34 (72.3) 0.087 
 
Male 28 (27.2) 15 (26.8) 13 (27.7)  
Ethnicity (%) Asian 5 (4.9) 4 (7.1) 1 (2.1) 0.093 




6 (5.8) 5 (8.9) 1 (2.1)  
 Unknown 17 (16.5) 7 (12.5) 10 (21.3)  
 Caucasian 73 (70.9) 40 (71.4) 33 (70.2)  
Mean baseline age, 
years (SD)  
77.90 (6.75) 74.61 (5.69) 81.83 (5.78) <0.001 
Baseline age, 
years (%) 80 or over 
44 (42.7) 12 (21.4) 32 (68.1) <0.001 
 70-79 49 (47.6) 34 (60.7) 15 (31.9)  
 60-69 10 (9.7) 10 (17.9) 0 (0.0)  
Mean baseline VA, 
ETDRS letters (SD) 
 54.6 (14.9) 56.6 (13.2) 52.2 (16.6) 0.139 
Baseline VA, 
ETDRS letters (%) 70 or over 
26 (25.2) 13 (23.2) 13 (27.7) 0.772 
 50-69 45 (43.7) 29 (51.8) 16 (34.0)  
 36-49 13 (12.6) 8 (14.3) 5 (10.6)  
 35 or less 19 (18.4) 6 (10.7) 13 (27.7) 0.098 









Patients, n (%)  103 56 (54.36%) 47 (45.63%)  
Mean baseline VA, ETDRS 
letters (SD)  
54.6 (14.9) 56.6 (13.2) 52.2 (16.6) 0.139 
Mean VA at 10 years or 
last visit, ETDRS letters 
(SD)  
42.2 (26.3) 42.9 (27.0) 41.4 (25.8) 0.767 
Mean change in VA at 10 
years or last visit, ETDRS 
letters (SD)  
-12.4 
(25.0) 
-13.7 (24.4) -10.7 (25.8) 0.566 
Fellow eye involved?  (%) No 38 (36.9) 17 (30.4) 21 (44.7) 0.195 
 Yes 65 (63.1) 39 (69.6) 26 (55.3)  
Mean time to fellow eye 
involvement, months (SD)  
30.55 
(30.53) 
37.90 (33.32) 19.54 
(22.09) 
0.016 




 37.04 (24.19) 14.94 (13.7) <0.001 
Mean injection number 
between both eyes (SD)  
42.7 (29.8) 53.6 (30.1) 24.9 (19.15) <0.05 








Stable at 10 years or at 
loss-to-follow-up? (%) No 
51 (49.5%) 29 (51.8) 22 (46.8)  
 Yes 52 (50.5%) 27 (48.2) 25 (53.2)  
Switch from ranibizumab 
to aflibercept (%)  
60 (58.3) 47 (83.9) 13 (27.7)  
Mean time of switch from 
ranibizumab to aflibercept, 
months (SD)  
65.58 
(9.50) 
65.55 (10.29) 65.69 (6.12) 0.963 
VA ≥ 70 at 10 years or last 
visit (%)  
20 (19.4) 12 (21.4) 8 (17.0) 0.754 
 
 
VA ≤ 35 at 10 years or last 
visit (%)  
41 (39.8) 23 (41.1) 18 (38.3) 0.933 









Mean CRT at 10 years or 








Mean change in CRT at 10 








Geographic atrophy at 10 
years or last visit (%) 
Total 77 (74.8%) 43 (76.8%) 34 (72.0) 0.77 
 Foveal 14 (13.6%) 5 (8.9%) 9 (19.0%) 0.17 
 Non-foveal 63 (61.2%) 38 (67.9%) 25 (53.2%)  
Fibrotic scar at 10 years or 
last visit (%) Total 
57 (55.3%) 32 (57.1%) 25 (53.2%) 0.84 
 Foveal 45 (43.7%) 21 (37.5%) 24 (51.1%) 0.01 
 Non-foveal 12 (11.7%) 11 (19.6%) 1 (2.1%)  
IRF only at 10 years or last 
visit (%)  
31 (30.9%) 21 (37.5%) 10 (21.7%) 0.63 
SRF only at 10 years or 
last visit (%)  
10 (9.7%) 5 (8.9%) 5 (10.1%) 0.24 
IRF and SRF at 10 years or 
last visit (%)  
10 (9.7%) 3 (5.4%) 7 (15.9%) 0.31 
Missing OCT (%)  1 (0.9%) 1 (1.8%) 0 (0.0%)  














Figure 2. ​Time-to-event analysis with outcome being visual acuity of less than or equal to 35                







Figure 3. ​Time-to-event analysis with outcome being visual acuity of greater than or equal to 70                








Figure 4.​ Mean trends in visual acuity (VA) of first-affected eyes with nAMD. Mean VA (a) and 
mean change in VA following baseline (b) in early treatment diabetic retinopathy study (ETDRS) 
letters over the 120 month observation period. Baseline was considered timepoint at which the 








(ETDRS) 95% CI 
Mean change in VA (ETDRS) 
from baseline 
 95% CI 
0 54.6 2.9 0 0 
6 57.9 4.0 1.9 3.3 
 
 
12 59.1 3.8 2.6 3.6 
24 56 4.3 -0.3 4.0 
36 55.8 5.0 -1.5 4.6 
48 56.5 4.8 -0.7 4.3 
60 49.7 5.4 -7.5 5.1 
72 50.7 5.8 -5.6 5.5 
84 47.6 6.1 -8.4 5.6 
96 46.8 7.1 -10.1 6.2 
108 47 6.6 -9.8 6.2 
120 42.9 7.2 -13.7 6.5 
 
Supplementary Table 1.​ Mean visual acuity (VA) and change in VA from baseline in early 








( ​μm) 95% CI 
Mean change in CRT 
thickness ( ​μm) from 
baseline 95% CI 
0 299 18.2 0 0 
6 246 23.5 -55.8 29.5 
12 262 14.9 -36.8 22.9 
24 249 15.4 -57.2 23.3 
36 241 18.3 -55.3 25.8 
48 242 15.9 -54.3 28.4 
60 245 19.8 -55.3 25.8 
72 253 54.9 -49.8 59.6 
84 237 22.4 -72.5 27.2 
96 266 52.5 -33.4 54.9 
108 299 46.3 1.59 49.7 
 
 
120 237 23.4 -54.7 29.5 
 
Supplementary Table 2.​ Mean central retinal thickness (µm) and change in central retinal 







in months from baseline 
Mean 
injections SD 
0 0 0 
12 5.33 3.09 
24 3.33 2.82 
36 3.01 2.90 
48 2.75 3.14 
60 2.86 3.22 
72 2.74 2.93 
84 2.42 2.92 
96 1.90 2.80 
108 1.67 2.88 
120 1.10 2.19 







Supplementary Figure 1. ​Overview of MEH AMD anti-VEGF treatment guidelines. ​(a) As 
per NICE guidelines, AMD patients are indicated for anti-VEGF therapy given the following: 
best-corrected visual acuity (VA) is between 6/12 and 6/96 Snellen (circa 73 to 25 ETDRS 
letters); no permanent structural damage to the central fovea; lesion size is less than or equal to 
12 disc areas in greatest linear dimension; evidence of recent presumed disease progression.  
At MEH, some patients initiated treatment with VA < 25 ETDRS letters as funding for therapy 
had been sought and approved at a time when VA was > 25 letters. (b) Early non-response was 
defined as worsening VA and/or OCT on the 3rd injection visit. Patients were reviewed in 4 
weeks for consideration of switching anti-VEGF agent or consideration of photodynamic therapy 
(PDT). (c) Therapy response-failure (as per NICE) refers to VA decline by 30 letters despite 
anti-VEGF. Here, a switch is considered if failure to one drug) or a drop to below 15 letters 
caused by the AMD lesion and no other cause can explain the visual loss. Treatment is 
otherwise withheld permanently. (d) Patients who failed to respond to aflibercept after 12 
months despite reducing dosing interval may consider switching to ranibizumab. (e) Disease 
and CNV inactivity is defined as absence of the following features when compared with the 
previous visit: new or enlargement of fluid on OCT; new or persistent haemorrhage or exudates; 
decreased VA attributable to CNV; fluorescein leakage or increase in lesion size on FFA.  With 
aflibercept, the monthly injections for initial 3 months are followed by 3 injections at 2-monthly 
intervals. At the 7th visit, if OCT imaging demonstrates wet features and/or VA decreases with 
residual fluid present the treatment interval is reduced down to 6 weekly and then 4 weekly until 
desired response is achieved. Once dry and/or stable, injection visits increase by 2-week 
increments (6-weekly, and then 8- weekly, etc). However, if at the 7th visit the OCT is dry and 
VA stable, intervals can increase to 10-weekly and then 12 weekly injections. As with 
ranibizumab, if a patient undergoes 12-weekly injections for 3 consecutive visits alongside 
features of disease stability, they are monitored at 6-weekly intervals for 6 months without 








Supplementary Figure 2. ​Outcomes of the better-seeing eye at baseline and at 10 years,              






Supplementary Figure 3. ​Time to GA. 
 
  
  
 
 
 
 
 
